Romiplostim (Nplate®) is indicated for the treatment of adult chronic ITP splenectomised patients who have had either an inadequate response or who are intolerant of corticosteroids and immunoglobulins and also as second line treatment for adult ITP non-splenectomised patients where surgery is contraindicated.
|02/04/2015||27/05/2015||Full Pharmacoeconomic Evaluation Recommended|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.
Romiplostim is indicated for chronic immune (idiopathic) thrombocytopenic purpura (ITP) in patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
The Applicant is seeking reimbursement under the High Tech Drug Arrangements.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||18/06/2019|
|Rapid review completed||18/07/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of romiplostim compared with the current standard of care.|